Mutational analysis of tyrosine kinase domain of BCR-ABL1 gene in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors

被引：0

作者：

Kihel, I. ^{[3
]}

Nachi, M. ^{[2
]}

Cayuela, J. ^{[3
]}

Bekadja, M. A. ^{[1
]}

Note, A. ^{[3
]}

机构：

[1] Fac Med Ahmed Ben Bella, Oran, France

[2] EHS BURN ORAN, Fac Med Ahmed Ben Bella, Med Biochem & Mol Biol Res Lab, Oran, France

[3] St Louis Hosp, Mol Lab, Paris, France

来源：

CLINICA CHIMICA ACTA | 2024年 / 558卷

关键词：

D O I：

10.1016/j.cca.2024.119279

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

引用

页数：1

共 50 条

[11] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
Gustafson, Dakota
Fish, Jason E.
Lipton, Jeffrey H.
Aghel, Nazanin
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (01) : 20 - 30
[12] β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
A M Eiring
J S Khorashad
D J Anderson
F Yu
H M Redwine
C C Mason
K R Reynolds
P M Clair
K C Gantz
T Y Zhang
A D Pomicter
I L Kraft
A D Bowler
K Johnson
M Mac Partlin
T O'Hare
M W Deininger
Leukemia, 2015, 29 : 2328 - 2337
[13] β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
Eiring, A. M.
Khorashad, J. S.
Anderson, D. J.
Yu, F.
Redwine, H. M.
Mason, C. C.
Reynolds, K. R.
Clair, P. M.
Gantz, K. C.
Zhang, T. Y.
Pomicter, A. D.
Kraft, I. L.
Bowler, A. D.
Johnson, K.
Mac Partlin, M.
O'Hare, T.
Deininger, M. W.
LEUKEMIA, 2015, 29 (12) : 2328 - 2337
[14] Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
Fominykh, Mikhail
Shuvaev, Vasily
Martynkevich, Irina
Shukhov, Oleg
Chelysheva, Ekaterina
Turkina, Anna G.
Abdulkadyrov, Kudrat
BLOOD, 2016, 128 (22)
[15] BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Press, Richard D.
Kamel-Reid, Suzanne
Ang, Daphne
JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (05): : 565 - 576
[16] Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Eide, Christopher A.
Bottomly, Daniel
Savage, Samantha L.
White, Libbey
Wilmot, Beth
Schultz, Anna M. Reister
Uchida, Kimberly A.
Agarwal, Anupriya
Traer, Elie
Beppu, Lan
Sala-Torra, Olga
Radich, Jerald P.
Eickelberg, Garrett
Press, Richard D.
Loriaux, Marc M.
Tantravahi, Srinivas K.
Pomicter, Anthony D.
Zabriskie, Matthew S.
Deininger, Michael W.
O'Hare, Thomas
Tyner, Jeffrey W.
McWeeney, Shannon K.
Tognon, Cristina E.
Druker, Brian J.
BLOOD, 2016, 128 (22)
[17] Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
Pinilla-Ibarz, Javier
Sweet, Kendra
Emole, Josephine
Fradley, Michael
ANTICANCER RESEARCH, 2015, 35 (12) : 6355 - 6364
[18] ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors
Shojaei, Mahboobeh
Rezvani, Hamid
Azarkeivan, Azita
Poopak, Behzad
LABORATORY MEDICINE, 2021, 52 (02) : 158 - 167
[19] MOLECULAR RESPONSE TO THERAPY WITH TYROSINE KINASE INHIBITORS IN PATIENTS WITH BCR-ABL1(+) CHRONIC MYELOID LEUKEMIA PRESENTING WITH AN ISOLATED THROMBOCYTOSIS AT THE ONSET
Balatzenko, G.
Hrischev, V.
Ignatova, K.
Stoyanova, Z.
Lilova, A.
Angelova, S.
Ivanova, S.
Romanova, M.
Ivanova, I.
Tsvetkova, G.
Hadjiev, E.
Madzharova, V.
Dikov, T.
Spassov, B.
Davidkova, Y.
Jagurinoski, M.
Guenova, M.
HAEMATOLOGICA, 2017, 102 : 733 - 733
[20] Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia
Vinhas, Raquel
Fernandes, Alexandra R.
Baptista, Pedro V.
MOLECULAR THERAPY-NUCLEIC ACIDS, 2017, 7 : 408 - 416

← 1 2 3 4 5 →